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ABSTRACT The P2-adrenergic receptor (32AR) can be
constitutively activated by mutations in the third intracellular
loop. Whereas the wild-type receptor exists predominantly in
an inactive conformation (R) in the absence of agonist, the
mutant receptor appears to spontaneously adopt an active
conformation (R*). We now demonstrate that not only is the
mutant I32AR constitutively active, it is also constitutively
desensitized and down-regulated. To assess whether the mutant
receptor can constitutively engage a known element of the
cellular desensitization machinery, the receptor was purified
and reconstituted into phospholipid vesicles. These prepara-
tions retained the essential properties of the constitutively
active mutant receptor: agonist-independent activity [to stim-
ulate guanine nucleotide-binding protein (G5)-GTPase] and
agonist-specific increase in binding affinity. Moreover, the
purified mutant receptor, in the absence of agonist, was
phosphorylated by recombinant PAR-specific kinase (PARK)
in a fashion comparable to the agonist-occupied wild-type
receptor. Thus, the conformation of the mutated receptor is
equivalent to the active conformation (R*), which stimulates G,
protein and is identical to the PJARK substrate.
Receptor activation by agonists is the first step in signal
transduction. It is generally considered that receptors exist in
an equilibrium between an inactive (R) and an active (R*)
conformation. The binding of agonists to receptors stabilizes,
and therefore shifts, the equilibrium toward the active con-
formation R* (1, 2). Adrenergic receptors (ARs) provide a
model for the family ofguanine nucleotide-binding protein (G
protein)-coupled receptors (3), and some recent studies have
provided evidence supporting this two-state model of recep-
tor activation: mutations in the C-terminal portion ofthe third
intracellular loop ofthe alB- (4, 5), (3- (6), and a2AR subtypes
(7) constitutively activate these receptors, leading to an
agonist-independent activation of the corresponding effector
enzymes. The properties of such constitutively active mutant
(CAM) receptors have been rationalized by assuming that
they preferentially adopt the active rather than the inactive
conformation and therefore spontaneously mimic an agonist-
occupied form of the receptor (6).
In addition to cellular activation, the binding of agonists to
cell surface receptors often results in a waning of cellular
responsiveness (desensitization). In the well-studied 132-
adrenergic system, such attenuation operates mainly at the
level of the receptor itself. Indeed, besides the activation of
adenylyl cyclase (AC) through the G, protein, the binding of
an agonist results in both receptor loss (down-regulation) and
receptor uncoupling from the G protein (8). Uncoupling from
the G protein results mainly from the receptor being phos-
phorylated by two kinases, cAMP-dependent protein kinase
and (3-adrenergic receptor-specific kinase (PARK) (9).
Inasmuch as a CAM receptor mimics an agonist-occupied
form of the receptor with respect to cellular activation
mechanisms, it might therefore also be expected to consti-
tutively engage the attenuation mechanisms that are normally
activated only by occupation of the wild-type (WT) receptor
by an agonist. To test this hypothesis, we have taken two
complementary approaches: (i) the signal transduction prop-
erties of the WT and CAM 32-adrenergic receptor (P32AR)
were assessed in stably transfected mammalian cells, and (ii)
the molecular mechanisms underlying these properties were
studied with purified and reconstituted preparations of these
receptors.
MATERIALS AND METHODS
Permanent Cell Lines. Establishment and maintenance of
clones permanently expressing theWTandCAM P2AR in the
Chinese hamster ovary (CHO) cell line, cell membrane
preparation, determination of receptor density, and AC as-
says were performed and analyzed as described (6).
AC Data Analysis. Sensitization was quantitated as the gain
of signal transduction efficacy, as detailed earlier (10). In
brief, after subtraction of basal activity, the concentration-
response curves of control and treated membranes were
fitted and compared by using the following algorithm (11):
E = Em{r"A'/(Ka + A)" + r"A"},
where E is the effect, Em is the maximal possible effect, A is
the agonist concentration, K. is the association constant of
the agonist-receptor complex, and n is a slope factor, which
was never significantly different from 1 in all experiments
presented here. X is a parameter describing the signal trans-
duction efficacy of the system and is estimated individually
for each curve, whereas all the other parameters are shared
for each pair of treated/control curves. When Tteated >
Tcontrol, Ttreated/Tcontrol is taken as a measure of sensitization(-fold). Intuitively, this parameter corresponds to the in-
crease of the receptor population that would give an equiv-
alent enhancement of receptor-modulated AC activity (sen-
sitization). Thus, a discrepancy between the variation of T
(determined by curve fitting) and the variation of receptor
density (determined through direct radioligand binding) re-
flects a modulation of receptor-effector coupling.
Purification and Reconstitution of the WT and Mutant
Mi6AR. The cDNAs encoding the WT and CAM 2AR (6, 12)
were subcloned into vector pAcC4 and cotransfected in Sf9
Abbreviations: SONAR, P2-adrenergic receptor; CAM, constitutively
active mutant; WT, wild type; AC, adenylyl cyclase; G protein,
GTP-binding regulatory protein; G,, AC-stimulatory G protein;
1BARK, BAR-specific kinase.
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FIG. 1. Constitutively active mutant P2AR. The C-terminal portion of the P2AR was substituted with the homologous region of the a1B
subtype, generating the indicated point mutations (6). Standard one-letter code for amino acids was used.
cells with linearized viral DNA (Baculogold transfection kit;
PharMingen) to produce recombinant baculovirus. Positive
viral clones were isolated by plaque assay, and the receptor
expression was measured by the binding of the P3AR-specific
ligand [125I]iodocyanopindolol (NEN). WT and CAM (2AR
were prepared from Sf9 cells as described (13). Briefly,
receptors were solubilized in 20 mM Tris HCl, pH 7.5/1.5%
digitonin/100 mM NaCl/2 mM EDTA, purified on an alpre-
nolol-Sepharose column, reconstituted in phosphatidylcho-
line vesicles as described (14), and stored at -700C.
Radblolgand Binding Asay. Binding of [125I]iodocyanopin-
dolol to P2AR on cell membranes was carried out as described(6). Binding assays on reconstituted receptors were per-















NaCl/0.05% digitonin. Bound and free radioligand were
separated by G-50 gel-filtration columns. All binding data
were subjected to nonlinear least-squares regression analysis
(15).
GTPase Assay. Heterotrimeric G, protein was purified as
described (16). Purified P2AR (100 fmol) and G, protein (50
fmol) were co-reconstituted in phospholipid vesicles, and
receptor-mediated GTPase activity was determined as de-
scribed (14).
Receptor Phosphorylation. Recombinant PARK was puri-
fied from baculovirus-infected Sf9 cells as described (17). The
reconstituted receptors were phosphorylated by BARK as
described (18) in the absence or presence of 100 mM isopro-
terenol (Sigma). At appropriate time intervals, reactions were
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FIG. 2. Sensitization ofCAM p2AR-coupled AC by betaxolol. Cells harboring the CAM P2AR at 200 fmol per mg ofmembrane protein were
incubated for 17 hr in ITS (Collaborative Research) supplemented serum-free F12 medium (GIBCO) containing 10 pM betaxolol (dashed curve)
or vehicle only (solid curve). Cell membranes were prepared as described (6) with the following modifications: lysis buffer (5 mM Tris HCl, pH
7.5/2mM EDTA) was supplemented with 10 pM betaxolol for cell lysis and the first rinse ofthe membrane fraction. Samples were then subjected
to three more sedimentation-resuspension cycles in lysis buffer devoid ofbetaxolol and subsequently assayed for AC activation by isoproterenol.
Data were normalized to the activity evoked by 100 pM forskolin (-25 pmol per min per mg of membrane protein). Solid curve, EC50 = 100
nM; dashed curve, ECso = 63 nM. Control and betaxolol-treated set of data were also compared to yield the increase of T that gauges the
enhancement of cyclase responsiveness (see Materials and Methods). In the experiment shown, Tsenistized/Tcontlr) = 6.4. (Inset) Receptor
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stopped with an equal volume of 2x SDS sample loading
buffer and electrophoresed on SDS/10%o polyacrylamide
gels. Phosphorylation stoichiometries were determined ei-
ther by excising and counting the receptor bands or by using
a PhosphorImager (Molecular Dynamics) as described (19).
RESULTS AND DISCUSSION
To test the hypothesis that constitutively active receptors
might also be constitutively desensitized, we sought means of
reversing the constitutive activity of the 32-CAM receptor
(Fig. 1). Betaxolol (a gift from Synthelabo, Bagneux,
France), a ,31-adrenergic antagonist, was found to repress this
basal activity (20). Incubation of cells expressing the CAM
receptor with betaxolol at the saturating concentration of 10
,uM for 17 hr led to both up-regulation of the receptor (Fig.
2 Inset) and sensitization of 8AR-coupled AC, as indicated
by a simultaneous increase in basal and maximal activities
(Fig. 2). No such effects were observed for the WT receptor
exposed to similar treatment (data not shown).
We next examined the respective contributions of the
increase in receptor density and the increase of receptor
coupling efficiency to the increase of AC responsiveness. A
numerical analysis was applied to the AC dose-response
curves, yielding estimates for a parameter (T) that gauges
variations of receptor-mediated cyclase activity (see Mate-
rials and Methods). The betaxolol treatment resulted in a 6.2
+ 0.2-fold sensitization of AC, while the binding site density
increased concomitantly by only 2.0 + 0.2-fold (mean +
SEM; n = 3; Fig. 2). Thus, AC sensitization in the presence
ofthe negative antagonist reflects an increase ofreceptor/AC
coupling in addition to receptor up-regulation. Moreover, the
treatment of cells with betaxolol, which increases the sensi-
tivity of AC to an adrenergic agonist, had no effect on the
sensitivity of AC to NaF and forskolin (direct activators of
the G protein and the catalytic moiety of cyclase, respec-
tively; data not shown). Thus, the CAM receptor in its native
state is both tonically down-regulated and partially uncou-
pled from the G protein.
These findings suggest that the CAM P2AR is able to
tonically engage not only G, protein but also various com-
ponents ofthe cellular desensitization machinery. To test this
hypothesis, we examined the role of a well-defined element
of this machinery: BARK-mediated phosphorylation of the
receptor (9). We first sought to obtain purified preparations
of both WT and CAM receptors for the purpose of compar-
ative studies.
The receptors were expressed in Sf9 cells by infection with
recombinant baculoviruses. Expression levels for the mutant
were =3 pmol per mg of membrane protein, as compared to
5-10 pmol per mg of membrane protein for the WT 32AR.
Both receptors were purified and reconstituted into phos-
pholipid vesicles (see Materials and Methods). The recon-
stituted mutant 832AR had a 20-fold higher affinity than the
WT receptor for the agonist isoproterenol, whereas both
receptors had identical affinities for the antagonist alprenolol
(Fig. 3A), in keeping with our previous observations in
membranes (6). Reconstitution of both receptors with puri-
fied G, protein yielded agonist-stimulated GTPase activities
(Fig. 3B). However, the agonist-independent GTPase-
stimulating activity of the CAM f2AR was comparable to the
agonist-dependent activity of the WT receptor. This finding
reproduces what we previously observed at the level of AC
stimulation for receptors in membranes (6). Controls with
receptors alone indicated the absence of contaminating
GTPase activity in the receptor preparations (data not
shown). Thus, the purified CAM P2AR exhibits the two major
properties of CAM receptors in membranes: (i) agonist-
specific, G-protein-independent affinity increase (Fig. 3A)
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FIG. 3. Properties of purified CAM and WT P2AR. (A) Ligand
binding. [125I]Iodocyanopindolol (CYP) binding to reconstituted WT
or mutant P2AR was determined as described. Results are represen-
tative of three independent experiments. Dissociation constants (Kj)
of isoproterenol (ISO) binding were 6.5 ± 1.8 and 0.33 ± 0.11 nM,
and those ofalprenolol (ALP) binding were 49 ± 7.1 and 37 ± 3.2 pM,
respectively, for WT or mutant P2AR. (B) Activation of G. protein.
P2AR (100 fmol) was reconstituted with 50 fmol of G. protein as
described (14) and preincubated on ice for 20 min in the absence or
presence of 100 A&M isoproterenol. Activation was conducted at 300C
for 20 min. Receptor-independent activity of the G protein, deter-
mined after reconstitution with heat-inactivated receptors, was sub-
tracted from all measurements. The agonist-independent (basal)
activity of the WT receptor was then taken as 100%o. Results are
means ± SE ofthree independent experiments. A typical experiment
yielded the following results: receptor-independent activity, 0.10 mol
of Pi per mol of G. per min; basal WT, 0.16 mol of Pi per mol of Gs
per min; isoproterenol-stimulated WT, 0.25 mol of Pi per mol of G.
per min; basal CAM, 0.24 mol of Pi per mol of G. per min;
isoproterenol-stimulated CAM, 0.26 mol of Pi per mol of G, per min.
3B). This indicates that purified preparations of the CAM
P2AR can be used to investigate the molecular basis of
constitutive desensitization.
We proceeded to assess SARK-mediated phosphorylation
of the purified receptors. As was previously observed (21),
little if any phosphorylation of the WT receptor occurs in the
absence of the agonist isoproterenol (Fig. 4A). However, the
CAM receptor shows considerable phosphorylation under
the same conditions (Fig. 4A). The rate and extent of the
agonist-independent phosphorylation ofthe CAM P2AR were
comparable to the agonist-dependent phosphorylation of the
WT P2AR (Fig. 4B). The maximal phosphorylation of the
CAM 32AR in the presence of isoproterenol was about twice
that of the WT P2AR (Fig. 4B). However, in the presence of
purified G-protein fBy subunits, which greatly enhance A2AR
phosphorylation by PARK (17), both receptors were maxi-
mally phosphorylated to =8 mol of Pi per mol (data not
shown). These results clearly demonstrate an agonist-inde-
pendent, pARK-mediated phosphorylation of the CAM
P2AR. Such spontaneous susceptibility to the PARK could in
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FIG. 4. Phosphorylation of f3ZAR by f3ARK in the absence or
presence of isoproterenol. (A) Reconstituted WT (Upper) or mutant
(Lower) IFAR (20 nM) was incubated at 300C with DARK (30 nM) in
20 nM Tris HCl, pH 8.0/2 mM EDTA/10 mM MgCl2/1 mM dithio-
threitol/100mM ATP (~2000 cpm/pmol) in the absence or presence
of isoproterenol (iso). Stoichiometries of Pi incorporation in A were
plotted against incubation time in B. Experiments were repeated
three times with similar results.
part account for the tonic uncoupling of the CAM (32AR from
the G protein indicated by the whole-cell data (see above) and
further demonstrates the equivalence of the unliganded CAM
($ZAR and the agonist-occupied WT I32AR with respect to
recognition by HARK.
Recent reports have revealed that point mutations are
sufficient to constitutively activate G-protein-coupled recep-
tors, some of which are involved in human diseases (re-
viewed in ref. 22). We previously investigated the effects of
these mutations in AR on the modulation of effector en-
zymes, such as AC and phospholipase C. However, another
important aspect of cell signaling is the ability of receptors to
mediate a loss of cellular responsiveness. In the present
report, we show that a mutant f$2AR that constitutively
activates the AC also engages cellular attenuation mecha-
nisms in an agonist-independent fashion. These include
down-regulation, receptor uncoupling, and pARK-mediated
phosphorylation. Interestingly, this suggests that the activity
of CAM receptors, both basal and agonist-stimulated, might
have been previously underestimated (6).
The properties of these mutants have been rationalized
within a theoretical model ofreceptor activation that involves
an allosteric transition between two putative conformations
of the receptor: one inactive (R), and the other (R*) capable
of activating the G protein (6). Constitutively activating
mutations were assumed to make the R to R* transition
agonist independent. However, the molecular nature of the
hypothetical active conformer R* has remained to be defined.
We confirm here that the activation properties of the mutant
receptor are conserved throughout purification and reconsti-
tution procedures. Furthermore, we demonstrate that the
ligand-free CAM N2AR has molecular properties close to
those of an agonist-occupied WT receptor. One such prop-
erty is the susceptibility to 3ARK-mediated phosphorylation
(19). The CAM receptor indeed undergoes PARK-mediated
phosphorylation even in the absence of agonist. The finding
that the agonist-independent phosphorylation of the CAM
receptor closely matches the agonist-induced phosphoryla-
tion of the WT receptor parallels our observation of the
corresponding G,-activating (this work) and AC-stimulating
(6) activities. In addition, we have previously shown that
when transfected in COS-7 cells, various CAM a2ARs are
subject to PARK-mediated, agonist-independent phosphor-
ylation in proportion to their constitutive activity (7). Taken
together, these findings suggest that constitutive activation
and susceptibility to PARK-mediated phosphorylation have
the same molecular basis. Thus, the results with the purified
CAM P2AR strengthen the idea that the postulated R*
conformer is equivalent to the PARK substrate.
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